Status:
RECRUITING
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Lead Sponsor:
Leiden University Medical Center
Conditions:
Adult Congenital Heart Disease
Congenital Heart Disease
Eligibility:
All Genders
18+ years
Brief Summary
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigati...
Detailed Description
In the adult congenital heart disease (ACHD) population, heart failure currently represents the main cause of morbidity and mortality. The etiology of ACHD-related heart failure is heterogenous, and t...
Eligibility Criteria
Inclusion
- Congenital heart defect.
- Age ≥ 18 years.
- Initiated on treatment with an SGLT2i.
Exclusion
- \- No consent for data collection.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06932081
Start Date
January 1 2023
End Date
December 31 2027
Last Update
April 23 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University
Baltimore, Maryland, United States, 21205
2
Helen DeVos Children's Hospital
Grand Rapids, Michigan, United States, 49503
3
Mount Sinai Fuster Heart Hospital
New York, New York, United States, 10029
4
Leiden University Medical Center (LUMC)
Leiden, South Holland, Netherlands, 2333ZA